Focused On-demand Library for 2'-5'-oligoadenylate synthase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

E18/E16; p46/p42 OAS

Alternative UPACC:

P00973; A8K4N8; F8VXY3; P04820; P29080; P29081; P78485; P78486; Q16700; Q16701; Q1PG42; Q3ZM01; Q53GC5; Q53YA4; Q6A1Z3; Q6IPC6; Q6P7N9; Q96J61


2'-5'-oligoadenylate synthase 1, known as E18/E16 or p46/p42 OAS, plays a pivotal role in the innate antiviral response. It synthesizes 2'-5'-oligoadenylates (2-5A) that activate RNase L, leading to viral and cellular RNA degradation. This enzyme is crucial for halting viral replication and is involved in apoptosis, cell growth, differentiation, and gene regulation. Its activity against viruses like VSV, HSV-2, and EMCV highlights its broad antiviral spectrum.

Therapeutic significance:

Given its role in Immunodeficiency 100 with pulmonary alveolar proteinosis and hypogammaglobulinemia, targeting 2'-5'-oligoadenylate synthase 1 offers a promising avenue for therapeutic intervention. Understanding its function could pave the way for novel treatments for viral infections and immune disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.